120 related articles for article (PubMed ID: 26144265)
21. Prediction of inhibitory activities of Hsp90 inhibitors.
Swuec P; Barlow DJ
Bioorg Med Chem; 2012 Jan; 20(1):408-14. PubMed ID: 22112537
[TBL] [Abstract][Full Text] [Related]
22. Ligand Binding Thermodynamics in Drug Discovery: Still a Hot Tip?
Geschwindner S; Ulander J; Johansson P
J Med Chem; 2015 Aug; 58(16):6321-35. PubMed ID: 25915439
[TBL] [Abstract][Full Text] [Related]
23. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
24. Microarray-based screening of heat shock protein inhibitors.
Schax E; Walter JG; Märzhäuser H; Stahl F; Scheper T; Agard DA; Eichner S; Kirschning A; Zeilinger C
J Biotechnol; 2014 Jun; 180():1-9. PubMed ID: 24667540
[TBL] [Abstract][Full Text] [Related]
25. Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics.
Lu H; Iuliano JN; Tonge PJ
Curr Opin Chem Biol; 2018 Jun; 44():101-109. PubMed ID: 29986213
[TBL] [Abstract][Full Text] [Related]
26. Hydration properties of ligands and drugs in protein binding sites: tightly-bound, bridging water molecules and their effects and consequences on molecular design strategies.
García-Sosa AT
J Chem Inf Model; 2013 Jun; 53(6):1388-405. PubMed ID: 23662606
[TBL] [Abstract][Full Text] [Related]
27. Group Additivity in Ligand Binding Affinity: An Alternative Approach to Ligand Efficiency.
Reynolds CH; Reynolds RC
J Chem Inf Model; 2017 Dec; 57(12):3086-3093. PubMed ID: 29111708
[TBL] [Abstract][Full Text] [Related]
28. A QSAR study on the inhibition mechanism of matrix metalloproteinase-12 by arylsulfone analogs based on molecular orbital calculations.
Hitaoka S; Chuman H; Yoshizawa K
Org Biomol Chem; 2015 Jan; 13(3):793-806. PubMed ID: 25406681
[TBL] [Abstract][Full Text] [Related]
29. Experiences in fragment-based lead discovery.
Hubbard RE; Murray JB
Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
[TBL] [Abstract][Full Text] [Related]
30. Molecular insights on TNKS1/TNKS2 and inhibitor-IWR1 interactions.
Kirubakaran P; Kothandan G; Cho SJ; Muthusamy K
Mol Biosyst; 2014 Feb; 10(2):281-93. PubMed ID: 24291818
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in the structure-based rational design of TNKSIs.
Zhan P; Song Y; Itoh Y; Suzuki T; Liu X
Mol Biosyst; 2014 Nov; 10(11):2783-99. PubMed ID: 25211064
[TBL] [Abstract][Full Text] [Related]
32. Physics-based scoring of protein-ligand interactions: explicit polarizability, quantum mechanics and free energies.
Bryce RA
Future Med Chem; 2011 Apr; 3(6):683-98. PubMed ID: 21554075
[TBL] [Abstract][Full Text] [Related]
33. E-novo: an automated workflow for efficient structure-based lead optimization.
Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
[TBL] [Abstract][Full Text] [Related]
34. Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases.
Bertini I; Calderone V; Fragai M; Giachetti A; Loconte M; Luchinat C; Maletta M; Nativi C; Yeo KJ
J Am Chem Soc; 2007 Mar; 129(9):2466-75. PubMed ID: 17269766
[TBL] [Abstract][Full Text] [Related]
35. Misuse of thermodynamics in the interpretation of isothermal titration calorimetry data for ligand binding to proteins.
Pethica BA
Anal Biochem; 2015 Mar; 472():21-9. PubMed ID: 25484232
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
37. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
[TBL] [Abstract][Full Text] [Related]
38. Hydantoin based inhibitors of MMP13--discovery of AZD6605.
De Savi C; Waterson D; Pape A; Lamont S; Hadley E; Mills M; Page KM; Bowyer J; Maciewicz RA
Bioorg Med Chem Lett; 2013 Aug; 23(16):4705-12. PubMed ID: 23810497
[TBL] [Abstract][Full Text] [Related]
39. Finding Hsp90 inhibitors by drug repurposing: the power of chemical genetics.
Xiong M; Zhang HY
Drug Discov Today; 2012 Jun; 17(11-12):531-3. PubMed ID: 22469949
[No Abstract] [Full Text] [Related]
40. Binding thermodynamics of substituted diaminopyrimidine renin inhibitors.
Sarver RW; Peevers J; Cody WL; Ciske FL; Dyer J; Emerson SD; Hagadorn JC; Holsworth DD; Jalaie M; Kaufman M; Mastronardi M; McConnell P; Powell NA; Quin J; Van Huis CA; Zhang E; Mochalkin I
Anal Biochem; 2007 Jan; 360(1):30-40. PubMed ID: 17113558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
